Seen in the ED: Sudden Left Upper Quadrant Pain, Normal Labs

Article

Slide Show Case Quiz

A man in his 50s is seen in the emergency department for acute LUQ pain. Vital signs are normal and so are results of laboratory studies. What do you see on CT? What's your Dx?

Find a myriad of puzzling presentations in our collection of Dr Pregerson's "Seen in the ED" cases.

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
FDA Approves AbbVie's Combination Antibiotic Emblaveo for Complicated Intra-Abdominal Infections

FDA Approves AbbVie's Combination Antibiotic Emblaveo for Complicated Intra-Abdominal Infections

Sydney Jennings
February 7th 2025
Article

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Grace Halsey
February 7th 2025
Article

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

FDA Grants Priority Review to Brensocatib, First Targeted Treatment for Bronchiectasis

FDA Grants Priority Review to Brensocatib, First Targeted Treatment for Bronchiectasis

Patient Care Editorial Staff
February 7th 2025
Article

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

US Dementia Cases to Double by 2060: Daily Dose / image credit: ©New Africa/AdobeStock

US Dementia Cases to Double by 2060: Daily Dose

Sydney Jennings
February 7th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.